Skip to content

Study · Non-randomized trial · n = 26 · 2001

8 results

Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy.

Broglio F, Benso A, Valetto MR, Gottero C, Quaranta L, Podio V, Arvat E, Bobbio M, Bisi G, Ghigo E

Endocrine1 Feb 2001Cited by 21 (Europe PMC)

PMID11322491 (opens in a new tab)DOI10.1385/endo:14:1:105 (opens in a new tab)PepBankPUB-11322491
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    Acute intravenous hexarelin caused no significant variation in mean blood pressure across normal, GH-deficient and cardiomyopathy groups.

    In plain wordsA single hexarelin injection did not change mean blood pressure in healthy adults or in the two patient groups.

    Peptide
    Hexarelin
    Outcome
    No significant changeMean blood pressure
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    without significant variations in MBP and HR.
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.
  2. 02HumanNon-randomized trialSafety outcome

    Acute intravenous hexarelin caused no significant variation in heart rate across normal, GH-deficient and cardiomyopathy groups.

    In plain wordsA single hexarelin injection did not change heart rate in healthy adults or in the two patient groups.

    Peptide
    Hexarelin
    Outcome
    No significant changeHeart rate
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    without significant variations in MBP and HR.
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with severe dilated cardiomyopathy, acute intravenous hexarelin did not significantly change left ventricular ejection fraction.

    In plain wordsIn people with severe dilated cardiomyopathy, a single hexarelin injection did not change the heart's ejection fraction.

    Peptide
    Hexarelin
    Outcome
    No significant changeLeft ventricular ejection fraction in dilated cardiomyopathy
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    Hexarelin signficantly (p < 0.05) increased LVEF in normal and in GH-deficient subjects, but not in dilated cardiomyopathy, without significant variations in MBP and HR.
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with dilated cardiomyopathy, acute intravenous hexarelin significantly increased growth hormone levels.

    In plain wordsIn people with dilated cardiomyopathy, a single hexarelin injection raised growth hormone levels.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH levels in dilated cardiomyopathy
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    Hexeralin significantly (p < 0.05) increased GH levels in normal subjects and in dilated cardiomyopathy but not in GH deficiency.
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.
  5. 05HumanNon-randomized trialEfficacy outcome

    In normal adults, acute intravenous hexarelin significantly increased left ventricular ejection fraction.

    In plain wordsIn healthy adults, a single hexarelin injection raised the heart's ejection fraction.

    Peptide
    Hexarelin
    Outcome
    IncreaseLeft ventricular ejection fraction in normal adults
    Study

    n = 7

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    Hexarelin signficantly (p < 0.05) increased LVEF in normal and in GH-deficient subjects
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with severe growth hormone deficiency, acute intravenous hexarelin significantly increased left ventricular ejection fraction.

    In plain wordsIn people with severe growth hormone deficiency, a single hexarelin injection raised the heart's ejection fraction.

    Peptide
    Hexarelin
    Outcome
    IncreaseLeft ventricular ejection fraction in GH deficiency
    Study

    n = 7

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    Hexarelin signficantly (p < 0.05) increased LVEF in normal and in GH-deficient subjects
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.
  7. 07HumanNon-randomized trialEfficacy outcome

    In normal adults, acute intravenous hexarelin significantly increased growth hormone levels.

    In plain wordsIn healthy adults, a single hexarelin injection raised growth hormone levels.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH levels in normal adults
    Study

    n = 7

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    Hexeralin significantly (p < 0.05) increased GH levels in normal subjects
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with severe growth hormone deficiency, acute intravenous hexarelin did not significantly increase growth hormone levels.

    In plain wordsIn people with severe growth hormone deficiency, a single hexarelin injection did not raise growth hormone levels.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH levels in GH deficiency
    Study

    n = 7

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2.0 microg/kg · intravenous · single acute dose, measured up to 60 minAs given in this study (human).

    Source sentences

    Summary
    Hexeralin significantly (p < 0.05) increased GH levels in normal subjects and in dilated cardiomyopathy but not in GH deficiency.
    1 context sentence
    Summary · context
    We studied in humans the cardiac effects of hexarelin administration in 7 normal adults, in 7 severe GH-deficient patients, and in 12 patients with severe dilated cardiomyopathy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.